binx health Announces Appointment of UnitedHealth Group’s Optum Rx Chief Financial Officer Jeff Grosklags to its Board of Directors

Boston, MA, Mrach 4, 2022 - binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today the appointment of Jeff Grosklags, an accomplished industry leader and UnitedHealth Group’s Optum Rx Chief Financial Officer (CFO) to its Board of Directors. For the past 16 years, Grosklags has worked in a financial leadership capacity within Optum and UnitedHealth Group.

“We are thrilled to welcome Jeff to the binx Board of Directors given his decades of business and healthcare leadership, and his passion for care access” said Jeff Luber, CEO of binx health. “In a rapidly changing environment for healthcare delivery, we are fortunate to have the breadth of talent we do in the binx board and know that Jeff will be an enormous complement to our mission of ‘Everywhere Care.’”

With more than 25 years of leadership experience, Grosklags brings significant strategic, operational, and financial expertise to the company. Currently, he is the CFO of Optum Rx, a UnitedHealth Group company, one of the largest pharmacy care service companies in the United States, serving 60 million Americans nationwide, 67,000 network pharmacies, and over $100B in managed drug spend. Prior to becoming CFO of Optum Rx, Grosklags held a number of senior leadership positions within UnitedHealth Group, including CFO of Optum Health Care Solutions, Optum Health Care Delivery and COO and CFO of Optum Financial Services. Prior to joining UnitedHealth Group in 2006, he served in a number of leadership positions at Metris Companies, including CFO of the credit card business and Senior Vice President of Finance. Grosklags previously served as a senior auditor for Deloitte and holds a degree in Business Administration with a concentration in accounting from the University of St. Thomas.

“Patients are looking beyond clinic settings and are demanding care solutions that fit their busy lifestyles.” Grosklags said. “binx is well positioned to play a significant role in this era of healthcare with their commitment to using innovation and technology to increase healthcare access and equity. I am excited to join the binx health board of directors.”

binx health is working to improve sexual health and wellness by providing convenient access to high-quality testing that prioritizes clinical integrity and consumer convenience. The binx health solutions are designed to break down screening barriers through point-of-care onsite solutions and discreet patient-tailored at-home sample collection offerings in order to reach patients “everywhere”. In response to the pandemic, in addition to sexual health and wellness, binx health added COVID-19 programs that have proven vital in helping their partners track, record and manage compliance with testing protocols.

About binx health

binx health is a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop. The Company works with large corporate partners and institutions who have access to large patient populations and have a significant interest in delivering or facilitating better healthcare to provide access to and enable more streamlined delivery of diagnostic testing and care. Its omnichannel platform includes the point-of-care* io *platform, which puts central-lab quality testing solutions in the hands of clinicians everywhere, and the Company's suite of physician-mediated and medical guideline-driven, at-home sample collection offerings, which bring high-quality testing, population health tools, and seamless digital integration capability to those unable or unwilling to visit a clinic location.

binx's* io* platform is the first ever FDA-cleared, CLIA-waived point-of-care tool for the detection of chlamydia and gonorrhea from male and female specimens that provides central lab performance results in about thirty minutes. Its platform is highly flexible, easy-to-use, and rapid, offering molecular point-of-care answers at central-lab quality performance and for the first time enabling single-visit test and treatment. For more information, visit www.binx.com.

Source